Pharmaceutical company Upsher-Smith Laboratories LLC reported on Friday the availability of Diphenoxylate Hydrochloride and Atropine Sulfate Tablets in USP, 2.5 mg/0.025 mg in the US.

The company said the Diphenoxylate Hydrochloride and Atropine Sulfate Tablets in USP, 2.5 mg/0.025 mg is an AA-rated generic version of the branded product, Lomotil (diphenoxylate hydrochloride and atropine sulfate tablets). Lomotil is a registered trademark of GD Searle LLC and the combination prescription drug is used to treat the symptoms of acute or chronic diarrhea.

For the 12 months ending May 2018, the diphenoxylate hydrochloride and atropine sulfate tablet market had US sales of approximately USD64m, according to IQVIA.

In conjunction, Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP are classified as a Schedule V controlled substance.